<DOC>
	<DOCNO>NCT01811160</DOCNO>
	<brief_summary>Schizophrenia bipolar disorder frequently associate elevate risk obesity , metabolic syndrome , diabetes mellitus , dyslipidemia metabolic disturbance . Second Generation Antipsychotics ( SGA ) demonstrate efficacy acute long term treatment disorder consider first option treatment guideline . Unfortunately use SGA associate drug induce weight gain , disturb glucose lipid regulation increase cardiovascular risk mortality well non- adherence treatment . There several hypothesis attempt explain complex pathway lead antipsychotic therapeutic effect accompany adverse effect . Recently , animal receive SGA , melatonin prevent large extent body weight increase , indicate possible role biological rhythm SGA induce body weight accumulation . Melatonin hormone secrete pineal gland follow circadian rhythm increase secretion middle night . This hormone act importantly suprachiasmatic nucleus area brain periphery . Thus melatonin involve series biological function sleep regulation , blood pressure , regulation circadian rhythm , mood , behavior , recently regulation metabolic process include insulin , leptin , lipid regulation . Given previous result experimental animal , purpose present study test potential effect melatonin reduce prevent metabolic disturbance associate SGA</brief_summary>
	<brief_title>Metabolic Effects Melatonin Patients Treated With Second Generation Antipsychotics</brief_title>
	<detailed_description />
	<mesh_term>Melatonin</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1 . Men nonpregnant , nonlactating woman age 18 45 year ; 2 . DSMIVTR criterion schizophrenia bipolar disorder type I ; 3. free concomitant medical neurological illness ( per review system general physical examination ) ; 4. free DSMIV current substance abuse history substance dependence last six month ; 5. initiate continuous treatment SGA ( clozapine , olanzapine , quetiapine risperidone ) period great last three month prior inclusion present study . 1. diagnosed hypertension , diabetes mellitus , dyslipidemia , thyroid disorder hepatic illness ; 2. history hypersensitivity melatonin ; 3. exhibit high risk suicide high risk aggressiveness ; 4. woman practice reliable form contraception . Patients eliminate study suspend SGA two consecutive dos study capsule point follow period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Melatonin</keyword>
	<keyword>Second generation antipsychotic</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>Metabolic</keyword>
</DOC>